OGYGIA Trademark

Trademark Overview


On Thursday, July 24, 2025, a trademark application was filed for OGYGIA with the United States Patent and Trademark Office. The USPTO has given the OGYGIA trademark a serial number of 99301669. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, July 24, 2025. This trademark is owned by Vanda Pharmaceuticals Inc.. The OGYGIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatme...
ogygia

General Information


Serial Number99301669
Word MarkOGYGIA
Filing DateThursday, July 24, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, July 24, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for treating hypertension; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of tyrosine kinase inhibitor (TKI)-induced diarrhea; Pharmaceutical preparations for the treatment of COVID-19; Pharmaceutical preparations for the treatment of inflammatory lung injury (ILI); Pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); Pharmaceutical preparations for the treatment of social anxiety disorder; Pharmaceutical preparations for the treatment of performance anxiety; Pharmaceutical preparations for the treatment of public speaking anxiety; Pharmaceutical preparations for the treatment of circadian rhythm disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of Smith-Magenis Syndome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of major depressive disorder (MDD); Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for the treatment of Charcot-Marie-Tooth disease; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of non-24 hour sleep-wake disorder (non-24)

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 24, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVanda Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Trademark Events


Event DateEvent Description
Thursday, July 24, 2025NEW APPLICATION ENTERED
Thursday, July 24, 2025APPLICATION FILING RECEIPT MAILED
Thursday, July 24, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED